SCHEMBL2170674

SCHEMBL2170674

COc1ccc(-c2ccc3[nH]c(=O)ccc3c2)c2cncnc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.40
OGT O15294 1/20 0.40
TP53 P04637 1/20 0.40
MAPT P10636 1/20 0.40
PIK3CD O00329 1/20 0.39
ABL1 P00519 1/20 0.39
EGFR P00533 1/20 0.39
HCK P08631 1/20 0.39
SRC P12931 1/20 0.39
KDR P35968 1/20 0.39
PIK3CA P42336 1/20 0.39
PIK3CB P42338 1/20 0.39
MTOR P42345 1/20 0.39
PIK3CG P48736 1/20 0.39
EPHB4 P54760 1/20 0.39
PRKDC P78527 1/20 0.39
CA12 O43570 1/20 0.38
CA9 Q16790 1/20 0.38
MAP3K11 Q16584 3/20 0.38
PRKCQ Q04759 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2172288 0.85 GLO1 (0.43) LMNAOGTTP53MAPTPIK3CD
SCHEMBL2172749 0.82 LMNA (0.44) LMNAOGTTP53MAPTPIK3CD
SCHEMBL2172286 0.81 TNKS2 (0.43) LMNAOGTTP53MAPTCA12
SCHEMBL2215379 0.79 LMNA (0.45) LMNAOGTTP53MAPTCA12
SCHEMBL2170590 0.78 PDE4B (0.52) LMNAOGTTP53MAPTCA12
SCHEMBL2172765 0.78 PDE4B (0.53) LMNAOGTTP53MAPTTNKS2
SCHEMBL2173289 0.74 PDE4B (0.46) LMNAOGTTP53MAPTCA12
SCHEMBL2170517 0.73 LMNA (0.39) LMNAOGTTP53MAPTCA12
SCHEMBL1081684 0.73 TNKS2 (0.61) LMNAOGTTP53MAPTABL1
SCHEMBL2215586 0.72 PDE3A (0.53) LMNAOGTTP53MAPTCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2348018-A1 HETEROCYCLIC BIARYL DERIVATIVE, AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT Kyorin Pharmaceutical Co., Ltd. (JP) 2011-07-27 EP disclosed
US-20110178041-A1 HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT KYORIN PHARMACEUTICAL CO., LTD. (JP) 2011-07-21 US disclosed
US-20110178041-A1 HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT KYORIN PHARMACEUTICAL CO., LTD. (JP) 2011-07-21 US disclosed
US-20110178041-A1 HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT KYORIN PHARMACEUTICAL CO., LTD. (JP) 2011-07-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178041-A1 HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT PDE3A, PDE2A, PDE3B LMNA 2863/4885OGT 3902/4885TP53 4674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.